 |
|
anti-myeloma cell surface antigen immunoconjugate BT-062
An immunoconjugate consisting of a monoclonal antibody directed against a highly-expressed myleoma cell surface antigen covalently attached to the maytansinoid DM4, a derivative of the cytotoxic agent maytansine (DM1), with potential antineoplastic activity. Anti-myeloma cell surface antigen immunoconjugate BT-062 binds to an unspecified cell surface antigen highly expressed on myeloma cells; upon internaliization the DM4 moiety is released, binding to tubulin and disrupting microtubule assembly/disassembly dynamics, which may result in the inhibition of cell division and cell growth of myeloma tumor cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Synonym: | | maytansinoid-conjugated anti-myeloma monoclonal antibody BT-062 | | | | Code name: | | BT-062 | | |
|
|
